Molecular radiotherapy (MRT) is a relatively novel anti-cancer treatment option utilising radiolabelled, tumour-specific vectors. Upon binding of these vectors to cancer cells, radioactive decay induces DNA damage and other effects, leading to cancer cell death. Treatment, e.g. [177Lu]Lu-octreotate for neuroendocrine tumours and [177Lu]Lu-PSMA for prostate cancer, are now being implemented in routine clinical practice around the world. Nonetheless, research into their underlying radiobiological effects is essential to further improve current treatment or formulate new ones. The purpose of the European Working Group on the Radiobiology of Molecular Radiotherapy is to promote knowledge, investment, and networking in this area. This report summarises recent research and insights presented at the second International Workshop on Radiobiology of Molecular Radiotherapy, held in London, UK, on March 13 and 14, 2023. The symposium was organised by members of the CRUK RadNet City of London and the European Working Group on the Radiobiology of Molecular Radiotherapy.
|Journal||Journal of Nuclear Medicine|
|Publication status||Accepted/In press - 20 Jun 2023|